Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ME-401 in relapsed/refractory indolent B-cell NHL (Japanese)
NCT03985189Phase 1Completed
- Sponsor
- Kyowa Kirin
- Start
- Apr 2019
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of zandelisib in B-cell non-Hodgkin lymphoma (B-NHL) (3 arms), sponsored by Kyowa Kirin. Primary endpoint: Treatment-Emergent Adverse Events at 1 year. Started Apr 2019; status: completed.
02
Drugs
zandelisib
03
Conditions
B-cell non-Hodgkin lymphoma (B-NHL)
Beyond the preview
Go deeper on NCT03985189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03985189.